<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04526808</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000149</org_study_id>
    <nct_id>NCT04526808</nct_id>
  </id_info>
  <brief_title>Effects of Low FODMAP Diet on Leaky Gut</brief_title>
  <official_title>Effects of Low FODMAP Diet on Leaky Gut and Mucosal Immune Cell Abundance in Diarrhea-predominant Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pathophysiology of Irritable bowel syndrome (IBS) is multifactorial involving complex&#xD;
      interplay of altered intestinal permeability, mucosal immune activation, visceral&#xD;
      hypersensitivity and gut dysbiosis. Although the exact triggers for these pathological&#xD;
      changes in IBS are not clear but diet might play an important role. In fact, several studies&#xD;
      have reported improvement in gastrointestinal symptoms on a diet low in FODMAPs (LFD) in&#xD;
      patients with IBS, specifically in diarrhea predominant IBS (IBS-D). However, the mechanism&#xD;
      of action of LFD is not well understood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>colonic permeability</measure>
    <time_frame>4 weeks</time_frame>
    <description>Lactulose:Mannitol ratio pre and post treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>colonic immune cells</measure>
    <time_frame>4 weeks</time_frame>
    <description>expression of tight junction proteins pre and post treatment using RT-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>colonic microbiome</measure>
    <time_frame>4 weeks</time_frame>
    <description>relative stool microbial abundance pre and post treatment measured using 16s RNA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>FODMAP diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FODMAP diet</intervention_name>
    <description>low FODMAP diet</description>
    <arm_group_label>FODMAP diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged 18-65 years at the time of screening&#xD;
&#xD;
          -  normal serum studies including serum tissue-transglutaminase antibodies, thyroid&#xD;
             stimulating hormone levels, C-reactive protein, complete blood count since the onset&#xD;
             of symptoms&#xD;
&#xD;
          -  normal stool studies including C diff testing, culture, ova and parasites since the&#xD;
             onset of symptoms&#xD;
&#xD;
          -  IBS-SSS score of â‰¥175 at the end of 7-day screening period&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  individuals already on a LFD or other dietary restriction such as gluten free diet&#xD;
             within the past 6 months&#xD;
&#xD;
          -  individuals with any known food allergy or insulin-dependent diabetes&#xD;
&#xD;
          -  known history of celiac disease, inflammatory bowel disease or microscopic colitis&#xD;
&#xD;
          -  prior small bowel or colonic surgery or cholecystectomy&#xD;
&#xD;
          -  pregnant patients&#xD;
&#xD;
          -  antibiotics in the past 3 months&#xD;
&#xD;
          -  those who regularly use mast cell stabilizers or anti-histaminic or non-steroidal&#xD;
             anti-inflammatory agents (NSAIDs) excluding daily baby aspirin or steroids or&#xD;
             bile-acid binder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Lembo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vivian Cheng</last_name>
    <phone>617.667.0682</phone>
    <email>vcheng2@bidmc.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Cheng</last_name>
      <phone>617-667-0682</phone>
      <email>vcheng2@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prashant Singh, MD</last_name>
      <email>singhpr@med.umich.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Anthony Lembo</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

